Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey.
Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey.
复制标题
DOI：
10.3390/ijerph8010222
复制
发表时间：
2011-01
影响因子：
--
通讯作者：
Cummings KM
中科院分区：
文献类型：
--
作者：
Fix BV;Hyland A;Rivard C;McNeill A;Fong GT;Borland R;Hammond D;Cummings KM
Varenicline是一种新的处方戒烟药物（SSM），自2006年8月1日起在美国上市，自2006年12月5日起在英国和其他欧盟国家上市，自2007年4月12日起在加拿大上市，自2008年1月1日起在澳大利亚上市。很少有基于人群的研究检查了伐尼克兰和其他戒烟药物的使用率。我们报告的数据来自ITC的四国调查，调查对象是美国、英国、加拿大和澳大利亚的吸烟者，他们在2006年的调查中报告了在过去一年中尝试戒烟的情况（n = 4 022名参与者），2007年（n = 3 790名参与者）和2008年调查（n = 2，735名参与者）受访者报告在每个调查波中使用各种戒烟药物戒烟，沿着人口统计学和吸烟者特征。在所有4个国家中，自我报告的任何戒烟药物的使用在3年期间均显著增加，其中美国的增加幅度最大。自引入以来，伐尼克兰已成为所有4个国家中第二大使用的戒烟药物，仅次于NRT。2006年至2008年，伐尼克兰的使用率在美国从0.4%增加到21.7%，在加拿大从0.0%增加到14.8%，在澳大利亚从0.0%增加到14.5%，在英国从0.0%增加到4.4%。相比之下，NRT和安非他酮的使用在每个国家保持不变。男性和非白人使用任何SSM的可能性显着降低，而受过教育的吸烟者使用任何SSM的可能性显着增加，包括伐尼克兰。我们的研究结果表明，引入伐尼克兰导致在戒烟尝试期间使用循证治疗的吸烟者数量增加，而不是简单地以牺牲其他药物为代价获得市场份额。从公共卫生的角度来看，应广泛传播关于提高药物使用者成功率和戒烟药物相对安全性的信息，以便平等地接触到所有社会经济分类的所有吸烟者。
Varenicline is a new prescription stop smoking medication (SSM) that has been available in the United States since August 1, 2006, in the United Kingdom and other European Union countries since December 5, 2006, in Canada since April 12, 2007, and in Australia since January 1, 2008. There are few population-based studies that have examined use rates of varenicline and other stop smoking medications. We report data from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and Australia who reported an attempt to quit smoking in past year in the 2006 survey (n = 4,022 participants), 2007 (n = 3,790 participants), and 2008 surveys (n = 2,735 participants) Respondents reported use of various stop smoking medications to quit smoking at each survey wave, along with demographic and smoker characteristics. The self-reported use of any stop smoking medication has increased significantly over the 3 year period in all 4 countries, with the sharpest increase occurring in the United States. Varenicline has become the second most used stop smoking medication, behind NRT, in all 4 countries since being introduced. Between 2006 and 2008, varenicline use rates increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained constant in each country. Males and non-whites were significantly less likely to report using any SSM, while more educated smokers were significantly more likely to use any SSM, including varenicline. Our findings suggest that the introduction of varenicline led to an increase in the number of smokers who used evidence-based treatment during their quit attempts, rather than simply gaining market share at the expense of other medications. From a public health perspective, messages regarding increased success rates among medication users and the relative safety of stop smoking medications should be disseminated widely so as to reach all smokers of all socioeconomic classifications equally.
登录
查看更多内容
影响因子：
5.2
作者：
West, R;DiMarino, ME;McNeill, A
通讯作者：
McNeill, A
影响因子：
12.7
作者：
Metzger, KB;Mostashari, F;Kerker, BD
通讯作者：
Kerker, BD
影响因子：
4.7
作者：
Lewis, Sarah A.;Haw, Sally J.;McNeill, Ann
通讯作者：
McNeill, Ann
影响因子：
10
作者：
Hubbard, R;Lewis, S;Britton, J
通讯作者：
Britton, J
影响因子：
5.2
作者：
Thompson, M. E.;Fong, G. T.;Laux, F. L.
通讯作者：
Laux, F. L.